3rd International AIDS Society Conference on HIV Pathogenesis and Treatment Rio de Janeiro - July 24 - 27, 2005

SAFETY, EFFICACY AND PHARMACOKINETICS OF RITONAVIR 400 MG - SAQUINAVIR 400 MG AND RIFAMPICIN COMBINED THERAPY IN HIV NAïVE PATIENTS WITH TUBERCULOSIS

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. WePe3.3C03

Cavalcanti Rolla V.¹, da Silva Vieira M.A.², Ferreira Filho M.¹, da Silva de Jesus C.³, da Silva Lourenço M.C.¹, Gonçalves Morgado M.³, Pereira Pinto D.¹, Werneck-Barroso E.^1
1Institute for Clinical Research Evandro Chagas, Fiocruz, Rio de Janeiro, Brazil, ²Institute of Thorax Diseases, UFRJ, Rio de Janeiro, Brazil, ³Oswaldo Cruz Institute, Rio de Janeiro, Brazil

INTRODUCTION: Treatment of tuberculosis (TB) and AIDS with rifampicin and ritonavir-saquinavir (RTV-SQV) is recommended in current guidelines although this association is not well studied in literature. Our aim is to access drug concentration, efficacy and safety of concomitant use of rifampicin and antiretroviral regimens containing RTV-SQV (400 – 400) in TB-HIV naïve patients.

METHODS: AIDS patients with TB diagnosis were enrolled (n=20). At day 0, TB treatment was introduced. At day 30, HAART (2 nucleoside analogs and RTV-SQV 400/400 mg b.i.d.) was initiated. Pharmacokinetics from serial blood samples was assayed with a validated reversed-phase HPLC method before HAART introduction, after 30 days of therapy and at the end of study (without rifampicin). Clinical evaluation was performed monthly and recorded vital signs, weight, karnofsky score and adverse events (AE). CD4 counts, viral load (VL) and genotyping test were collected at baseline, D30 and D180. Primary endpoints were: drug concentration and viral load at D180 (<80 copies). Secondary endpoints were the presence of grade 3 and 4 AE, clinical improvement, CD4 counts, and genotypic resistance to RTV-SQV.

Results: We included 20 patients with TB-HIV diagnosis. Mean baseline CD4 counts was 152 cells/mm³ (± 146) and baseline VL was 5,34 log (± 0,4). During the study 15 patients dropped out, 14 because of AE (hepatic and gastrointestinal were the most frequents). One patient (among 5) presented VL <80 copies at D180. All but one increased baseline CD4 counts. No genotypic resistance was detected. Clinical improvement was evident in all (n=5) patients who tolerated the therapy. A decrease in AUC and an extended elimination half-life of RTV-SQV was observed during rifampicin therapy but concentrations were in the therapeutic range.

CONCLUSIONS: Although therapeutic levels of the studied drugs were achieved and VL reduced we do not recommend this regimen for naïve patients because AE are the major cause of treatment abandon.

Download PDF of this abstract.

050724
Clinical | WePe3.3C03 | Valeria Cavalcanti Rolla
Drug Interactions

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.